|
1
|
Zuo T, Zeng H, Li H, Liu S, Yang L, Xia C,
Zheng R, Ma F, Liu L, Wang N, et al: The influence of stage at
diagnosis and molecular subtype on breast cancer patient survival:
A hospital-based multi-center study. Chin J Cancer. 36:842017.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Coates AS, Winer EP, Goldhirsch A, Gelber
RD, Gnant M, Piccart-Gebhart M, Thürlimann B, Senn HJ, Panel
Members, André F, et al: Tailoring therapies-improving the
management of early breast cancer: St gallen international expert
consensus on the primary therapy of early breast cancer 2015. Ann
Oncol. 26:1533–1546. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kumar P and Aggarwal R: An overview of
triple-negative breast cancer. Arch Gynecol Obstet. 293:247–269.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Parikh RR, Yang Q, Higgins SA and Haffty
BG: Outcomes in young women with breast cancer of triple-negative
phenotype: The prognostic significance of CK19 expression. Int J
Radiat Oncol Biol Phys. 70:35–42. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lehmann BD, Pietenpol JA and Tan AR:
Triple-negative breast cancer: Molecular subtypes and new targets
for therapy. Am Soc Clin Oncol Educ Book. e31–e39. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gao D, Zhang X, Liu B, Meng D, Fang K, Guo
Z and Li L: Screening circular RNA related to chemotherapeutic
resistance in breast cancer. Epigenomics. 9:1175–1188. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Song J, Yin J, Bai Z, Zhang J, Meng H, Cai
J, Deng W, Ma X and Zhang Z: The profile of serum microRNAs
predicts prognosis for resected gastric cancer patients receiving
platinum-based chemotherapy. Dig Dis Sci. 62:1223–1234. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yang M, Li Y, Ruan Y, Lu Y, Lin D, Xie Y,
Dong B, Dang Q and Quan C: CLDN6 enhances chemoresistance to ADM
via AF-6/ERKs pathway in TNBC cell line MDAMB231. Mol Cell Biochem.
443:169–180. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li Z, Chen Z, Hu G and Jiang Y: Roles of
circular RNA in breast cancer: Present and future. Am J Transl Res.
11:3945–3954. 2019.PubMed/NCBI
|
|
10
|
Jahani S, Nazeri E, Majidzadeh AK, Jahani
M and Esmaeili R: Circular RNA; a new biomarker for breast cancer:
A systematic review. J Cell Physiol. 235:5501–5510. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Guo JU, Agarwal V, Guo H and Bartel DP:
Expanded identification and characterization of mammalian circular
RNAs. Genome Biol. 15:4092014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Meng S, Zhou H, Feng Z, Xu Z, Tang Y, Li P
and Wu M: CircRNA: Functions and properties of a novel potential
biomarker for cancer. Mol Cancer. 16:942017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shen Z, Zhou L, Zhang C and Xu J:
Reduction of circular RNA Foxo3 promotes prostate cancer
progression and chemoresistance to docetaxel. Cancer Lett.
468:88–101. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sang Y, Chen B, Song X, Li Y, Liang Y, Han
D, Zhang N, Zhang H, Liu Y, Chen T, et al: circRNA_0025202
regulates tamoxifen sensitivity and tumor progression via
regulating the miR-182-5p/FOXO3a axis in breast cancer. Mol Ther.
27:1638–1652. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Akram M and Siddiqui SA: Breast cancer
management: Past, present and evolving. Indian J Cancer.
49:277–282. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yin Y, Wang X, Li T, Ren Q, Li L, Sun X,
Zhang B, Wang X, Han H, He Y, et al: MicroRNA-221 promotes breast
cancer resistance to adriamycin via modulation of PTEN/Akt/mTOR
signaling. Cancer Med. 9:1544–1552. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Vasan N, Baselga J and Hyman DM: A view on
drug resistance in cancer. Nature. 575:299–309. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Nikolaou M, Pavlopoulou A, Georgakilas AG
and Kyrodimos E: The challenge of drug resistance in cancer
treatment: A current overview. Clin Exp Metastasis. 35:309–318.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liang Y, Song X, Li Y, Su P, Han D, Ma T,
Guo R, Chen B, Zhao W, Sang Y, et al: circKDM4C suppresses tumor
progression and attenuates doxorubicin resistance by regulating
miR-548p/PBLD axis in breast cancer. Oncogene. 38:6850–6866. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Dou D, Ren X, Han M, Xu X, Ge X, Gu Y,
Wang X and Zhao S: CircUBE2D2 (hsa_circ_0005728) promotes cell
proliferation, metastasis and chemoresistance in triple-negative
breast cancer by regulating miR-512-3p/CDCA3 axis. Cancer Cell Int.
20:4542020. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Jing L, Wu J, Tang X, Ma M, Long F, Tian B
and Lin C: Identification of circular RNA hsa_circ_0044556 and its
effect on the progression of colorectal cancer. Cancer Cell Int.
20:4272020. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yamaguchi R, Lartigue L and Perkins G:
Targeting Mcl-1 and other Bcl-2 family member proteins in cancer
therapy. Pharmacol Therap. 195:13–20. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tang YY, Zhao P, Zou TN, Duan JJ, Zhi R,
Yang SY, Yang DC and Wang XL: Circular RNA hsa_circ_0001982
promotes breast cancer cell carcinogenesis through decreasing
miR-143. DNA Cell Biol. 36:901–908. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gao M, Miao L, Liu M, Li C, Yu C, Yan H,
Yin Y, Wang Y, Qi X and Ren J: miR-145 sensitizes breast cancer to
doxorubicin by targeting multidrug resistance-associated protein-1.
Oncotarget. 7:59714–59726. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ding Y, Zhang C, Zhang J, Zhang N, Li T,
Fang J, Zhang Y, Zuo F, Tao Z, Tang S, et al: miR-145 inhibits
proliferation and migration of breast cancer cells by directly or
indirectly regulating TGF-β1 expression. Int J Oncol. 50:1701–1710.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chen S, Li F, Xu D, Hou K, Fang W and Li
Y: The function of RAS mutation in cancer and advances in its drug
research. Curr Pharm Des. 25:1105–1114. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Druillennec S, Pouponnot C and Eychène A:
NRAS-driven melanoma: A RAF can hide another. Mol Cell Oncol.
4:e13447582017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Banys-Paluchowski M, Milde-Langosch K,
Fehm T, Witzel I, Oliveira-Ferrer L, Schmalfeldt B and Müller V:
Clinical relevance of H-RAS, K-RAS, and N-RAS mRNA expression in
primary breast cancer patients. Breast Cancer Res Treat.
179:403–414. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Prior IA, Lewis PD and Mattos C: A
comprehensive survey of Ras mutations in cancer. Cancer Res.
72:2457–2467. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Song YK, Wang Y, Wen YY, Zhao P and Bian
ZJ: MicroRNA-22 suppresses breast cancer cell growth and increases
paclitaxel sensitivity by targeting NRAS. Technol Cancer Res Treat.
17:15330338188099972018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Li X, Liu Y, Zhang X, Shen J, Xu R, Liu Y
and Yu X: Circular RNA hsa_circ_0000073 contributes to osteosarcoma
cell proliferation, migration, invasion and methotrexate resistance
by sponging miR-145-5p and miR-151-3p and upregulating NRAS. Aging
(Albany NY). 12:14157–14173. 2020. View Article : Google Scholar : PubMed/NCBI
|
